Collegium Pharmaceutical vs Pacira BioSciences
COLL and PCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COLL and PCRX compare
Pacira BioSciences is the larger company, worth 1.8 times as much as Collegium Pharmaceutical ($1.5B against $824M).
On earnings, Collegium Pharmaceutical is cheaper: it trades at 25.3× trailing earnings, against 39.2× for Pacira BioSciences.
Collegium Pharmaceutical grew revenue faster over the last twelve months (7.7% versus 3.7% for Pacira BioSciences).
Pacira BioSciences keeps more of each dollar of sales as profit, with a net margin of 5.1% compared with 4.7% at Collegium Pharmaceutical.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COLL | PCRX |
|---|---|---|
| Size and price | ||
| Market cap | $824M | $1.5B |
| Share price | $25.32 | $36.46 |
| Change, 1 year | −46.5% | 52.8% |
| Change, 5 years | 34.3% | −34.6% |
| Beta (5Y) | 0.47 | 0.79 |
| Employees | 423 | 829 |
| StockData Score | ||
| Total score | 9 | 9 |
| Valuation score | 2 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 25.3× (better) | 39.2× |
| P/S | 1.0× (better) | 2.0× |
| P/B | 2.8× | 2.0× (better) |
| EV/EBITDA | 5.5× (better) | 12.2× |
| P/FCF | 2.5× (better) | 8.6× |
| FCF yield | 40.8% (better) | 11.6% |
| Fair value | $44.42 | $40.93 |
| Margin of safety | 43.0% (better) | 10.9% |
| Growth | ||
| Revenue growth (TTM) | 7.7% (better) | 3.7% |
| Revenue growth, 5Y average | 20.3% (better) | 11.1% |
| Net income growth (TTM) | −34.7% | 76.0% (better) |
| EPS growth (TTM) | −37.9% | 102% (better) |
| EPS growth, 5Y average | 17.9% (better) | −45.5% |
| Profitability | ||
| Gross margin | 59.0% | 78.7% (better) |
| Operating margin | 15.2% (better) | 4.8% |
| Net margin | 4.7% | 5.1% (better) |
| FCF margin | 41.3% (better) | 22.7% |
| Return on equity | 13.4% (better) | 5.2% |
| Return on invested capital | 160% (better) | 4.6% |
| Financial health | ||
| Debt / equity | – | 0.41 |
| Net debt / EBITDA | – | −0.02 |
| Interest coverage | 1.6× | 2.5× (better) |
| Current ratio | 1.01 | 4.68 (better) |
| Altman Z-score | 0.81 | 2.77 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 6.8% |
| Shareholder yield | 0.00% | 6.8% (better) |
| Ownership | ||
| Held by institutions | 121% | 110% |
| Held by insiders | 4.3% | 6.1% |
| Insider net buying, 12 months | −$4.4M | −$2.4M (better) |
| Short interest, % of float | 16.7% | 8.9% |
Go deeper
- COLL stock overview
- COLL income statement
- COLL valuation and score
- PCRX stock overview
- PCRX income statement
- PCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.